Skip to Content

The Cigna Group

CI: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$925.00YcrjzyGfvjjtk

Cigna Turns in Solid Q4 and 2023 Guidance; No Fair Value Estimate Change

Narrow-moat Cigna turned in strong fourth-quarter results that allowed the firm to exceed our expectations for 2022 a bit. However, that mild outperformance combined with 2023 guidance that looks roughly in line with our expectations was not enough to change our $321 fair value estimate. Shares appear about fairly valued, to us.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CI so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center